Eli Lilly leads incretins via Zepbound/Mounjaro, retatrutide at 28.7% loss, $50B R&D and US buildout, 2025 guidance, ...

Retatrutide, originally developed by Eli Lilly, has found a loyal fan base—even though clinical trials of the drug still ...

Retatrutide is an investigational triple agonist developed by Eli Lilly that targets GLP-1, GIP and glucagon receptors, and ...

Lilly’s closely watched retatrutide spurred as much as 29% weight loss in a Phase 3 study, a finding that is “raising the bar ...

Eli Lilly highlighted its drug's effectiveness in helping people lose weight. Pharmaceutical giant Eli Lilly that new preliminary research indicates its medication Zepbound helps patients lose more ...

Eli Lilly's decision to reduce the price of its popular weight loss drug makes more sense than it appears at first. The ...

Eli Lilly cuts cash prices for Zepbound weight-loss vials on LillyDirect, offering doses from $299 to $449 as demand for ...

Discover why Wave Life Sciences Ltd. is a high-risk, high-reward biotech with unique RNA therapies for AATD, obesity, and ...

They’re definitely easier and more affordable than injectables, but do they work as well? Here’s what you need to know.

New obesity treatments, including ‘oral Mounjaro’ and ‘high-dose Wegovy,’ are scheduled to launch next year. The Danish pharmaceutical company Novo Nordisk’s oral obesity drug is entering the final ...

Eli Lilly and Company (LLY) is a global pharmaceutical leader focused on discovering, developing, and commercializing ...

Eli Lilly slashes Zepbound to £227 ($299) monthly for US cash payers, but just £31 ($41) in India – though £241 ($319) in ...